Dutasteride

A consensus of experts identified seven recommended interventions for AGA, including oral and topical finasteride, dutasteride, and minoxidil, while identifying 17 interventions that are not recommended.

Dutasteride (0.5 mg and 2.5 mg) is significantly more effective than finasteride (1 mg) at increasing hair counts in both males and females with AGA.

The review discusses the potential of topical dutasteride and nanocarrier delivery systems to provide an effective alternative to oral treatments while minimizing systemic absorption.

Oral dutasteride demonstrates better efficacy than finasteride for AGA with similar tolerability, while topical delivery methods like microneedling or mesotherapy may reduce systemic adverse events.

Various over-the-counter, prescription, and procedural treatments successfully promote hair growth, suggesting that a multifaceted, individualized approach is most effective.

Low-dose oral minoxidil has demonstrated a favorable efficacy and safety profile for both male and female androgenetic alopecia.

Various treatments including 5-alpha reductase inhibitors, oral minoxidil, and PRP show efficacy, though evidence for some newer or non-pharmacological methods remains limited.

Dutasteride 0.5 mg/d is ranked as the most effective treatment, followed by higher doses of finasteride and minoxidil.

The review concludes that finasteride and dutasteride can cause persistent sexual, neurological, and physical side effects in a subset of men, constituting post-finasteride syndrome, for which no evidence-based treatments currently exist.

Finasteride and minoxidil can halt disease progression but only yield partial hair regrowth; early initiation improves outcomes, and PRP may be considered for patients unresponsive to medical therapy.

The meta-analysis found that treatment with finasteride or dutasteride for male androgenetic alopecia is associated with an increased risk of sexual dysfunction, with finasteride showing a statistically significant 66% higher risk compared to placebo, while dutasteride showed a non-significant 37% increase.

First-line therapies recommended include oral finasteride 1 mg daily, oral dutasteride 0.5 mg daily, topical 5% minoxidil twice daily for MPHL and topical 1% minoxidil twice daily for FPHL, along with low-level laser therapy and hair transplantation.

The review highlights several emerging therapies, including novel excipients for oral minoxidil, dutasteride, and finasteride; topical prostaglandin modulators; low-level laser therapy; Wnt pathway activators and stem cell treatments for androgenetic alopecia; JAK inhibitors for alopecia areata; antiandrogens and pioglitazone for frontal fibrosing alopecia; and robotic-assisted follicular unit extraction for hair transplantation.

Treatments such as topical minoxidil and 5‑alpha reductase inhibitors (finasteride, dutasteride) can slow hair loss progression and promote regrowth, but continuous use is required to maintain benefit.

Dutasteride 0.5 mg significantly increased hair count and width and improved hair growth compared to both finasteride 1 mg and placebo.